anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Levemir
Trial phase: Phase 4
SMILES: CCCCCCCCCCCCCC(=O)NCCCCC(NC(=O)C1CCCN1C(=O)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(Cc1ccccc1)NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C1CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C2CSSCC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(NC(=O)C(NC(=O)CN)C(C)CC)C(C)C)C(=O)NC(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)N1)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)N2)C(C)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 82
Group description: Insulin treatment to target blood glucose at 180 mg/dl

Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
Eligibility criteria:
Inclusion Criteria:

Require Liver Transplantation
Age 18 - 80
Able to give informed consent personally or via a family member who has appropriate authorization to do so if patient unconscious.
Expected survival following transplantation for > 1 year.
Glucose level over 180 mg/dL postoperatively

Exclusion Criteria:

Inability of patient or family member to give informed consent
Not expected to survive for > 1 year following liver transplantation.
Previous liver transplantation
Acute liver failure
Living related donor
Intervention: Naltrexone
Trial phase: Phase 3
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: Male
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Naltrexone chlorhydrate 50 mg

Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil.
Eligibility criteria:
Inclusion Criteria:

severe alcohol dependence
no history of allergic processes, hepatic, cardiovascular, renal, pulmonary, endocrine or neurological pathologies, as well as no history of psychiatric disorders, dependences other than alcohol and/or tobacco, and blood test results outside the reference range

Exclusion Criteria:

history of allergic processes, hepatic, cardiovascular, renal, pulmonary, endocrine or neurological pathologies
dependences other than alcohol and/or tobacco
psychiatric disorders
test laboratories results outside the reference range
Intervention: (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
Trial phase: Phase 3
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O.CCC=CCC=CCC=CCCCCCCCC(=O)O
Sex: Male
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;

Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;
Eligibility criteria:
Inclusion Criteria:

severe alcohol dependence
no history of allergic processes, hepatic, cardiovascular, renal, pulmonary, endocrine or neurological pathologies, as well as no history of psychiatric disorders, dependences other than alcohol and/or tobacco, and blood test results outside the reference range

Exclusion Criteria:

history of allergic processes, hepatic, cardiovascular, renal, pulmonary, endocrine or neurological pathologies
dependences other than alcohol and/or tobacco
psychiatric disorders
test laboratories results outside the reference range
Intervention: Gadoterate Meglumine
Trial phase: Phase 3
SMILES: CNCC(O)C(O)C(O)C(O)CO.O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 240
Group description: Dotarem and Magnevist were randomised as 2:1 ratio for adults
Eligibility criteria:
Inclusion Criteria:

Adult subject and pediatric subjects (aged greater than or equal to two (2) years).
Is referred for a contrast-enhanced MRI of the CNS based on the results of a previous imaging procedure.
Female of childbearing potential patients must have effective contraception (contraceptive pill or intra-uterine device) or be surgically sterilized or post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI.
Has been fully informed about the study, and has consented to participate.

Exclusion Criteria:

Having acute or chronic grade IV or V renal insufficiency.
Known class III/IV congestive heart failure.
Suffering from long QT syndrome.
Unstable health condition or circumstances (e.g. suffering from severe claustrophobia).
Having any contraindications to MRI such as a pace-maker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field.
Known allergy to Gadolinium chelates.
Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration.
Pregnant, breast feeding, or planning to become pregnant during the trial.
Previously participated in this trial.
Having participated within 30 days in another clinical trial involving an investigational drug.
Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits.
Inability or unwillingness to cooperate with the requirements of this trial.
Intervention: Gadoterate Meglumine
Trial phase: Phase 3
SMILES: CNCC(O)C(O)C(O)C(O)CO.O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: children were only assigned to Dotarem
Eligibility criteria:
Inclusion Criteria:

Adult subject and pediatric subjects (aged greater than or equal to two (2) years).
Is referred for a contrast-enhanced MRI of the CNS based on the results of a previous imaging procedure.
Female of childbearing potential patients must have effective contraception (contraceptive pill or intra-uterine device) or be surgically sterilized or post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI.
Has been fully informed about the study, and has consented to participate.

Exclusion Criteria:

Having acute or chronic grade IV or V renal insufficiency.
Known class III/IV congestive heart failure.
Suffering from long QT syndrome.
Unstable health condition or circumstances (e.g. suffering from severe claustrophobia).
Having any contraindications to MRI such as a pace-maker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field.
Known allergy to Gadolinium chelates.
Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration.
Pregnant, breast feeding, or planning to become pregnant during the trial.
Previously participated in this trial.
Having participated within 30 days in another clinical trial involving an investigational drug.
Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits.
Inability or unwillingness to cooperate with the requirements of this trial.
Intervention: OXYTOCIN
Trial phase: Phase 1
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Twice daily intranasal oxytocin spray

intranasal oxytocin spray: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
Eligibility criteria:
Inclusion Criteria:

Daily consumption of 6 or more alcohol drinks/day for at least 2 weeks prior to admission.

Only one of the following two conditions must be met:

At least one prior episode 2 days or longer in duration which the subject experienced withdrawal symptoms that caused significant incapacitation.
At least one prior inpatient or outpatient medical detoxification during which the subject exhibited withdrawal symptoms that sedative-hypnotic or anticonvulsant medication was required at least once on 2 consecutive days after cessation of or reduction in the use of alcohol following 2 weeks or more of heavily daily consumption (6 or more drinks/day).

Exclusion Criteria:

Low literacy as indicated by an inability to read and understand the consent form.
Dependence on substances other than alcohol, nicotine, caffeine or cannabis.
History of alcohol withdrawal-related seizures, delirium tremens or hallucinations.
Current or past alcohol-related medical complications (e.g. cirrhosis of the liver, esophageal varices, severe gastritis, hemoptysis, hematochezia or melena).
Current delirium, disorientation to place or persons, seizures, acute or unstable psychosis or mania.
Suicidal or homicidal ideation with strong intent, plans or recent attempt.
Debilitating medical conditions (including AIDS, seizure disorder, emphysema, cancer and not well-controlled diabetes/hypertension) [HIV infection, diabetes, hypertension and asthma will not be grounds for exclusion]
Diagnosis of amnesia, dementia, cognitive impairment or significant neurological symptoms.
Low body weight (BMI<17).
History of anorexia nervosa or bulimia in the past 2 years.
Significant trauma, self injurious behavior or surgery in the previous 2 months
Pregnancy; giving birth or breast-feeding in the past 6 months.
Ingestion during the 2 weeks prior to this admission of much more alcohol/day than during previous drinking binges that preceded the onset of alcohol withdrawal symptoms.
Ingestion of more than 450 ml of alcohol/day.
Chronic treatment with benzodiazepines, barbiturates, anticonvulsants or stimulants
Treatment/ingestion in the 72 hours prior to enrollment in the study with long half-life benzodiazepines or sedative hypnotic drugs.
A blood alcohol level upon admission > 300 mg/dl.
Well-documented history of inadequately treated baseline hypertension or tachycardia (SBP>150 or DBP>100 or P>110).
Intervention: Carbidopa
Trial phase: Phase 3
SMILES: C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: carbidopa

Carbidopa : The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
Eligibility criteria:
Inclusion Criteria:

Male of female patients aged 12 and older
Confirmed diagnosis of familial dysautonomia by genetic testing.
Symptoms of severe nausea
Written informed consent or ascent to participate in the pilot trial and understanding that they can withdraw consent at anytime without affecting their future care.
Ability to comply with the requirements of the study procedures, including taking blood pressure measurements at home.

Exclusion Criteria:

Patients taking metroclopromide, domperidone, risperidone or other dopamine blockers
Patients taking MAO-inhibitors
Patients taking tricyclic antidepressants
Patients taking neuroleptic drugs (haloperidol and chlorpromazine)
Patients with a known hypersensitivity to any component of this drug.
Patients with atrial fibrillation, angina or an electrocardiogram documenting significant abnormality that may jeopardize the patient's health.
Patients with significant pulmonary, liver, renal (creatinine >2.0 mg/ml) or cardiac illness
Patients who are unable to clearly identify and rate their symptoms of nausea.
Women who are pregnant or lactating
Patients who have a significant abnormality on clinical examination that may, in
Intervention: Esmolol
Trial phase: Not Applicable
ATC code: C07AB09
SMILES: COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 70
Group description: esmolol: esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
Eligibility criteria:
Inclusion Criteria:

adult patients scheduled for cardiac surgery at LLUMC University Hospital will be eligible for participation in this study.

Exclusion Criteria:

severe LV (left ventricle)dysfunction (EF < 35%).
emergency procedures.
procedures with combined carotid artery surgery.
patients at high risk for stroke.
hemodynamically significant dysrhythmias.
pre-existing atrial fibrillation or high degree AV (atrioventricular block).
pacemaker dependency.
known sensitivity to beta blockers.
patient refusal.
Intervention: Nitroglycerin
Trial phase: Not Applicable
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 70
Group description: nitroglycerin: nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
Eligibility criteria:
Inclusion Criteria:

adult patients scheduled for cardiac surgery at LLUMC University Hospital will be eligible for participation in this study.

Exclusion Criteria:

severe LV (left ventricle)dysfunction (EF < 35%).
emergency procedures.
procedures with combined carotid artery surgery.
patients at high risk for stroke.
hemodynamically significant dysrhythmias.
pre-existing atrial fibrillation or high degree AV (atrioventricular block).
pacemaker dependency.
known sensitivity to beta blockers.
patient refusal.
Intervention: Adapalene
Trial phase: Phase 2
ATC code: D10AD03 | D10AD53
SMILES: COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Differin® 0.3% Gel Adapalene 0.3%

Topical to the face Once daily application in the evening for the first 4 weeks and twice daily application in the morning and in the evening for the following 20 weeks.
Eligibility criteria:
Inclusion Criteria:

Male or female subjects of any race, aged 18 to 50 years inclusive
Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion Criteria:

Subjects with active inflammatory acne lesions
Subjects with hypertrophic acne scars
Intervention: Lidocaine
Trial phase: Not Applicable
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: This group will be those randomized to receiving the intervention with 2% lidocaine gel.

2% lidocaine gel: Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.

Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room.
Eligibility criteria:
Inclusion Criteria:

Self-select either a Paragard or Mirena IUD and are appropriate for insertion as determined by their provider
Age 18-45
Speak English or Spanish

Exclusion Criteria:

Lidocaine allergy
First trimester abortion or miscarriage in the previous six weeks
Second trimester abortion or miscarriage in the previous 12 weeks
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: IBI-10090 513ug
Eligibility criteria:
Inclusion Criteria:

Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

Exclusion Criteria:

Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
Patients with any signs of intraocular inflammation in either eye at screening.
Patients who have received any prior intravitreal injections in the study eye.
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: IBI-10090 776ug
Eligibility criteria:
Inclusion Criteria:

Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

Exclusion Criteria:

Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
Patients with any signs of intraocular inflammation in either eye at screening.
Patients who have received any prior intravitreal injections in the study eye.
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: IBI-10090 1046ug
Eligibility criteria:
Inclusion Criteria:

Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

Exclusion Criteria:

Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
Patients with any signs of intraocular inflammation in either eye at screening.
Patients who have received any prior intravitreal injections in the study eye.
Intervention: Leuprolide
Trial phase: Phase 2
ATC code: L02AE02 | L02AE51
SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.

inhaled carbon monoxide: The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
Eligibility criteria:
Inclusion Criteria:

Adults above the age of 18 and equal to or below the age of 85
Diagnosis of IPF by biopsy or
American Thoracic Society (ATS)/European Respiratory Society (ERS)/ Latin American Thoracic Association (ALAT) Guidelines (Am J Respir Crit Care Med Vol 183. pp 788-824,2011)
Forced vital capacity (FVC) greater than or equal to 50% predicted, greater than or equal to one month off all medications prescribed for IPF

Exclusion Criteria:

Evidence of active infection within the last month
Significant obstructive respiratory defect
Supplemental oxygen required to maintain an oxygen saturation over 88% at rest
History of myocardial infarction within the last year, heart failure within the last 3 years or cardiac arrhythmia requiring drug therapy
History of smoking within 4 weeks of screening
Pregnancy or lactation
Participation in another therapeutic clinical trial
Intervention: 4-((2R)-4-tert-Butylpiperazine-2-carbonyl)-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide
Trial phase: Phase 2
SMILES: CC(C)(C)N1CCNC(C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(F)c3)CC2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: Two 50 mg AZD2423 tablets, once daily for 28 days
Eligibility criteria:
Inclusion Criteria:

Male or female of non-child bearing potential. Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
Between 40 and 80 years of age at Visit 1
Clinical diagnosis of COPD (GOLD stage 2 or 3)
FEV1/FVC <70% and FEV1 between 30 and 80% of the predicted normal post-bronchodilator (GOLD stage 2 or 3)
Current or ex-smokers

Exclusion Criteria:

Any clinically significant disease or disorder (including history of abnormal immune function) which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
Any lung disease other than COPD, recent respiratory infections which have not resolved fully, active tuberculosis or at risk of reactivation of tuberculosis.
Any abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability to take part or influence the results of the study
Immunisation with a live vaccine within 3 months or other vaccination within 30 days before planned start of treatment
Worsening of COPD symptoms within 4 weeks prior to start of study needing hospitalisation, oral steroids or antibiotics.